To this end, we used Pmel-1 TCR transgenic CD8+ T cells (29) that can recognize gp100 expressed on B16 tumor cells lacking CX3CL1 expression (30) and evaluated the potential intratumoral differentiation of tumor-specific CD8+ T cells. Here, CX3CL1 is linked to neoplasm.